Cost of Detecting Malignant Lesions by Endoscopy in 2741 Primary Care Dyspeptic Patients Without Alarm Symptoms

 Conflicts of Interest The authors disclose the following: Nicholas J. Talley, MD–Consultant: Altana, AstraZeneca, Axcan, Chugai, EBMed, Giaconda, GlaxoSmithKline, Kosan, KV Pharmaceuticals, Medscape, ProEd Communications, Renovis, Inc, Solvay, Strategic Consultants International, Takeda Pharmaceuticals, TAP Pharmaceutical Products, Inc, Therapeutic Gastrointestinal Group, Theravance, and Yamanouchi; Research Support: Merck, Novartis, Tap Pharmaceuticals, Axcan, Bohringer-Ingelheim, and Forest. Nimish Vakil, MD–Consultant: AstraZeneca, Takeda, Axcan, Xenoport, Orexo, and Merlion; Grant support: Astra-Zeneca, AGI, Xenoport, Eisai, and Addex. Sander Veldhuyzen van Zanten, MD–Research support: AstraZeneca; Speaker: AstraZeneca; Advisory Boards: National (in Canada) and International for AstraZeneca. Nigel Flook, MD–Continuing Medical Learning–Development: Abbott, Altana, AstraZeneca, Axcan, Bristol-Meyers Squibb, GlaxoSmithKline, Hoffman La Roche, McNeill, Janssen-Ortho, Merck, Novartis, Oryx, Parkhurst, Pfizer, Sanofi Aventis, Schering, Whitehall Robins, and Wyeth; Speaker: Abbott, AstraZeneca, Bristol-Meyers Squibb, GlaxoSmithKline, Hoffman La Roche, McNeill, Janssen-Ortho, Merck, Novartis, Pfizer, Sanofi Aventis, Whitehall Robins, and Wyeth; Advisory Board Member: AstraZeneca, Bristol-Meyers Squibb, Janssen-Ortho, Oryx, and Pfizer; Research: AstraZeneca, Novartis, and Sanofi Aventis. The remaining authors disclose no conflicts.

 Funding This research was supported by AstraZeneca R&D Sweden. The sponsor did not play any role in the calculations or in the writing of the manuscript.

PII: S1542-3565(09)00317-6

doi:10.1016/j.cgh.2009.03.031

© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.